Unlike ER-positive and HER2-enriched breast cancers have effective hormonal (e.g., tamoxifen) and targeted (e.g., Herceptin) therapies, respectively, the conventional chemotherapy is still a main regiment for treating TNBCs. The gene discussed is ERBB2; the disease is breast cancer.